NCT04735471View on ClinicalTrials.gov

A Phase 1 Study of ADI-001 in B Cell Malignancies

PHASE1TerminatedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

March 4, 2021

Primary Completion Date

February 3, 2025

Study Completion Date

February 3, 2025

Conditions
Lymphoma, FollicularLymphoma, Mantle-CellMarginal Zone LymphomaPrimary Mediastinal B-cell LymphomaDiffuse Large B Cell LymphomaLymphoma, Non-Hodgkin
Interventions
GENETIC

ADI-001

Anti-CD20 CAR-T

DRUG

Fludarabine

Chemotherapy for Lymphodepletion

DRUG

Cyclophosphamide

Chemotherapy for Lymphodepletion

Trial Locations (10)

14263

Roswell Park Cancer Institute, Buffalo

30342

Northside Hospital Blood and Marrow Transplant Group of Georgia, Atlanta

33136

University of Miami- Sylvester Comprehensive Cancer Center, Miami

40207

Norton Cancer Institute, Louisville

52242

The State University of Iowa, Iowa City

53226

Medical College of Wisconsin, Milwaukee

75204

Baylor Scott & White Research Institute, Dallas

77030

MD Anderson Cancer Center, Houston

94305

Stanford University Medical Center, Stanford

98104

Swedish Cancer Center, Seattle

Sponsors
All Listed Sponsors
lead

Adicet Therapeutics

INDUSTRY

NCT04735471 - A Phase 1 Study of ADI-001 in B Cell Malignancies | Biotech Hunter | Biotech Hunter